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Abstract 
Multicentric reticulohistiocytosis is a rare disease affecting skin and joints primarily and rarely other organs. We pre‑
sent a case report of this disease and an extensive review of the literature. We reviewed the data between 1991 and 
2014 and extracted 52 individual cases. Only articles in English were chosen after checking for relevance. The articles 
were studies and data was extracted into excel spread sheets and later used to compute such variables like frequency, 
mean and percentage of distribution of various clinical manifestations. The treatments used in these articles were 
critically analyzed and graded for their relative efficacy for skin and joint manifestations. The grades were 0 = worse, 
1 = no benefit/condition remained same, 2 = improvement without resolution, and 3 = resolution. This article also 
reports the demographic, clinical, laboratory and pathological data from the reviewed articles. Authors attempted to 
discuss the findings of this review in depth to help manage this condition and proposed a treatment algorithm to 
help clinicians approach this rare and challenging disease.
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Background
Multicentric reticulohistiocytosis (MRH) is a rare sys-
temic disease that can produce skin changes (usually 
papulo-nodular eruption), mucosal lesions, and arthritis, 
generally with erosive. It can rarely affect internal organs 
such as the lungs (resulting in pleural effusion) and heart 
(case reports of pericardial effusion and congestive heart 
failure), in addition to rare cases of mesenteric lymphad-
enopathy and urogenital lesions (Islam et al. 2013).
MRH is classified as non-Langerhans cell histiocytosis-
class II b, per the Histiocyte Society recommendations 
(Zelger et  al. 1996). It was first identified as a separate 
disease entity by Weber and Freudenthal (1937) with 
the term being coined by Goltz and Laymon (1954). 
Barrow et al. (1969) provided the first working definition 
of MRH.
At this time, there is not published data on incidence 
and prevalence of MRH. It has only largely been reported 
in single case studies. There are approximately 300 cases 
of MRH reported (Lesher and Allen 1984), mostly in 
Western countries and Japan. However, MRH is likely a 
world-wide disease with increased awareness and report-
ing in these certain regions. A recent article quotes MRH 
to more commonly affect females (2–3:1) (Tajirian et al. 
2006) with mean presentation between 40 and 50 years of 
age (Luz et al. 2001).
Early and accurate diagnosis of MRH is crucial. When 
untreated, MRH can cause erosive arthritis with poten-
tial progression to arthritis mutilans. Skin manifestations 
may be the presenting, and sometimes only, sign of the 
disease. Biopsies from both skin and synovium may dem-
onstrate numerous histiocytes with multinucleated giant 
cells and ground-glass appearing eosinophilic cytoplasm. 
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The histiocytes contain periodic acid-Schiff (PAS) posi-
tive material.
We present a case of MRH and share our experience 
with treatment regimens. Additionally, we present a com-
prehensive review of the literature with attention to fre-
quency of clinical manifestations, comorbid conditions, 
treatments, and treatment outcomes/benefits. Based 
upon this data, we have developed a suggested treatment 
algorithm.
Case report
We present a case of a healthy 63-year-old Caucasian 
man who had simultaneous onset of skin lesions, joint 
pain, and morning stiffness of up to 2  h duration. He 
also reported a subjective fever, weight loss (10 lbs.), 
and weakness. On clinical exam, the patient had red-
brown macules and papules symmetrically distributed 
on the dorsum of hands, elbows, periocularly, and per-
iauricularly (Figs.  1, 2). Yellow translucent firm pap-
ules were noted on the helix of the left ear, glabella, and 
bilateral eyebrows. There was no lymphadenopathy. 
Joint examination revealed swelling and tenderness in 
proximal and distal interphalangeal joints (PIPs, DIPs), 
metacarpophalangeal joints (MCPs), elbows, shoulders, 
and knees.
An aspirate from his knee effusion revealed a total 
nucleated count of 5540/mm3 with 16  % neutrophils, 
54  % lymphocytes, and 30  % monocytes. Synovial fluid 
analysis did not reveal crystals and cultures were nega-
tive. Serum laboratory studies were unremarkable, 
including erythrocyte sedimentation rate (ESR), com-
plete blood cell counts, liver and renal function tests. His 
antinuclear antibody (ANA) and rheumatoid factor were 
negative.
Initial clinical differential diagnosis included dermato-
myositis, rheumatoid arthritis, and psoriatic arthritis. A 
skin biopsy demonstrated numerous multinucleated his-
tiocytes infiltrating between the collagen bundles in the 
superficial dermis (Fig.  3). There is a Grenz zone sepa-
rating the epidermis from the dermal tumor. The multi-
nucleated histiocytes are large with an eosinophilic and 
finely granular “ground-glass” cytoplasm. The nuclei are 
haphazardly arranged, but tend to favor the center of the 
cells (Fig. 4). Additionally, there are an increased number 
of blood vessels amongst the histiocytes, as well as scat-
tered lymphocytes. A CD163 stain was diffusely positive 
and the cells were focally PAS-positive diastase-resistant. 
The cells were negative for S100. Polarization did not 
reveal and polarizable material. These findings are diag-
nostic of MRH.
Radiographs of the hands showed erosions in the left 
third DIP and right second DIP, in addition to mild joint 
space narrowing with mild diffuse osteopenia. There 
were also erosions seen in the scaphoid bone with sur-
rounding soft tissue swelling (Fig.  5). Given the age of 
Fig. 1 The patient’s right dorsal hand with visible swelling of all the 
distal, proximal interphalangeal and metacarpophalangeal joints
Fig. 2 The right dorsal hand with multiple red-brown macules and 
papules
Page 3 of 13Tariq et al. SpringerPlus  (2016) 5:180 
the patient concomitant osteoarthritis is the most likely 
cause of joint space narrowing. The patient’s left shoul-
der X-ray showed marked glenohumeral joint space 
narrowing, small humeral head osteophytes, subchon-
dral sclerosis, subchondral cysts (Fig.  6), and large ero-
sions of the humeral head. The bones were diffusely 
demineralized. Magnetic resonance imaging (MRI) of 
the shoulder showed moderate glenohumeral joint effu-
sion with synovitis and well-demarcated erosions of the 
humeral head (Fig.  7). We performed an ultrasound on 
the second right MCP (Fig.  8) and first Interphalangeal 
joint which showed minimal effusion but marked syno-
vial proliferation with moderate Doppler flow, suggesting 
disease activity. An ultrasound of the knee showed a large 
anechoic effusion, echogenic synovial proliferation with 
grade 2 Doppler flow (Fig. 9).
Given the association of MRH with internal malig-
nancy (Trotta et  al. 2004), the patient underwent can-
cer screening. This screening included colonoscopy and 
chest/abdominal computed tomography (CT). Purified 
Fig. 3 Skin biopsy from a red-brown papule on the right dorsal hand 
(Fig. 2) demonstrated numerous multinucleated histiocytes (arrows) 
infiltrating between the collagen bundles in the superficial dermis. 
There is a Grenz zone separating the epidermis from the dermal 
tumor. Additionally, there are an increased number of blood vessels 
amongst the histiocytes, as well as scattered lymphocytes
Fig. 4 The multinucleated histiocytes (arrows) are large with an 
eosinophilic and finely granular “ground‑glass” cytoplasm. The nuclei 
are haphazardly arranged, but tend to favor the center of the cells. 
A CD163 stain was diffusely positive and the cells were focally PAS‑
positive diastase‑resistant
Fig. 5 Radiographs of the hands showed erosions in the left third DIP 
and right second DIP, mild joint space narrowing with mild diffuse 
osteopenia, and erosions of the scaphoid bone with surrounding soft 
tissue swelling
Fig. 6 Radiograph of the left shoulder revealing marked gleno‑
humeral joint space narrowing, small humeral head osteophytes, 
subchondral sclerosis, and subchondral cysts
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protein derivative (PPD) skin test was negative. He was 
initially started on prednisone and methotrexate 20 mg/
week with subsequent improvement in the appearance of 
his cutaneous disease. Due to continued pain and joint 
swelling after 3 months of treatment, he was started on 
adalimumab 40  mg subcutaneously every other week 
which was eventually increased to weekly dosing. Alen-
dronate (70 mg weekly) was also started because of evi-
dence in the literature of benefit in patients with MRH.
Over a follow-up period of 4 years the patient’s disease 
symptoms were largely controlled on the above medica-
tion regimen. However, imaging continued to show effu-
sions in the hand joints and marked synovial proliferation 
in multiple MCPs, PIPs, and DIPs. Also, despite most of 
his symptoms improving, he had continued prominent 
right shoulder pain, with progressive disease shown on 
MRI, requiring joint replacement. He continued the use 
of the above medication regimen, and was able to taper 
his prednisone to 3 mg daily. Throughout his course, he 
continued to have radiologic evidence of disease despite 
relatively good symptom control.
Methods
We performed a Pubmed search using the key words 
“multicentric reticulohistiocytosis” and limiting the 
results to those published between the years 1991–2014, 
yielding 227 articles. These articles were then individu-
ally screened for inclusion criteria including a diagnosis 
of MRH, written in the English language, and discussed 
treatment regimen and outcome. We reviewed the treat-
ment options available (Islam et  al. 2013; Zelger et  al. 
1996; Weber and Freudenthal 1937; Goltz and Laymon 
1954; Barrow and Holubar 1969; Lesher and Allen 1984; 
Tajirian et  al. 2006; Luz et  al. 2001; Trotta et  al. 2004; 
Havill et  al. 1999; Lonsdale-Eccles et  al. 2009; Muñoz-
Santos et al. 2007; Goto et al. 2003; Bennàssar et al. 2011; 
Iwata et al. 2012; Hiramanek et al. 2002; Sakamoto et al. 
2002; Cox et al. 2001; Flaming and Weigand 1993; Olson 
et al. 2015; Aouba et al. 2015; Eagle et al. 1995; Han et al. 
2012; Teo and Goh 2009; Kishikawa et  al. 2007; Valen-
cia et al. 1998; Shiokawa et al. 1991; Moreau et al. 1992; 
Lambert and Nuki 1992; Qureshi et  al. 1993; Gibson 
et al. 1995; Franck et al. 1995; Liang and Granston 1996; 
Kocanaogullari et al. 1996; Gorman et al. 2000; Morris-
Jones et al. 2000; Hsu et al. 2001; Saito et al. 2001; Santilli 
et  al. 2002; Blanco et al. 2002; Outland et al. 2002; Hsi-
ung et al. 2003; Matejicka et al. 2003; Liu and Fang 2004; 
Kovach et al. 2004; Shannon et al. 2005; Mavragani et al. 
2005; Malik et al. 2005; Gajic-Veljic et al. 2006; Adamo-
poulos et al. 2006; Chen et al. 2006; Chauhan et al. 2007; 
de Zwart-Storm et al. 2007; Codriansky et al. 2008; Satoh 
et  al. 2008; Kalajian and Callen 2008; Broadwell et  al. 
2010; Kaul et al. 2010; Fett and Liu 2011; Mun et al. 2012; 
Yeter and Arkfeld 2013) and have summarized them in 
Table 1.
The articles were then reviewed in depth with data 
collected including patient demographics, cutaneous 
Fig. 7 MRI of the shoulder showing moderate glenohumeral joint 
effusion with synovitis and large well‑demarcated erosions on the 
humeral head
Fig. 8 Color Doppler imaging demonstrating a minimal effusion but 
marked synovial proliferation with moderate Doppler flow
Fig. 9 Large anechoic effusion and echogenic synovial proliferation 
with hypervascularity
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and extra cutaneous manifestations, comorbid condi-
tions, histological biopsy findings, laboratory stud-
ies, treatment regimens, and treatment outcomes. We 
graded the treatment response for each medication 
used with special attention to skin and joint disease. 
The following system was used to indicate the treat-
ment responses; 0  =  worse, 1  =  no benefit/condition 




Race and ethnicity Thirty-nine of the 52 cases reported 
race/ethnicity. Fifteen cases (29 %) noted ethnicity to be 
“White,” 13 cases (25  %) reported origin from the “Far 
East,” 6 cases (11.5  %) reported race as “Black,” 3 cases 
(5.7  %) reported race as “Hispanic,” 1 case reported 
“Indian” origin, and 1 case reported “Middle Eastern” 
origin.
Table 1 Summary of the different treatments used with relative benefit
Data not available for blank boxes
n = total number of patients
Medical treatments 
and indication
n total n (%) for score 3 = 
resolution of the 
condition
n (%) for score 
2 = improvement 
without resolution
n (%) for score 1 = no 
benefit/condition 
remained same
n (%) for score 0 = 
worse than prior to 
treatment
Methotrexate for arthritis 25 7 (28) 11 (44) 3 (12) 4 (16)
Methotrexate for skin 26 10 (38) 10 (28) 3 (11) 3 (11)
Hydroxychloroquine arthritis 7 0 (0) 1 (14) 3 (43) 3 (43)
Hydroxychloroquine skin 7 0 (0) 1 (14) 3 (43) 3 (43)
Thalidomide 1 1 (100)
Sulfasalazine arthritis 1 1 (100)
Sulfasalazine skin 1 1 (100)
Leflunomide arthritis 2 2 (100)
Leflunomide skin 2 2 (100)
Azathioprine arthritis 2 1 (50) 1 (50)
Azathioprine skin 2 1 (50) 1 (50)
Cyclophosphamide arthritis 10 2 (20) 4 (40) 4 (40)
Cyclophosphamide skin 11 3 (27) 5 (45) 3 (27)
Cyclosporine arthritis 1 1 (100)
Cyclosporine skin 2 1 (50) 1 (50)
Etanercept arthritis 6 3 (50) 2 (33) 1 (17)
Etanercept skin 6 3 (50) 2 (33) 1 (17)
Adalimumab arthritis 2 2 (100)
Adalimumab skin 2 2 (100)
Infliximab arthritis 3 1 (33) 2 (67)
Infliximab skin 3 1 (33) 2 (67)
Alendronate arthritis 4 1 (25) 2 (50) 1 (25)
Alendronate skin 4 2 (50) 1 (25) 1 (25)
Zolendronic acid arthritis 3 1 (33) 2 (67)
Zolendronic acid skin 2 1 (50) 1 (50)
Pamidronate arthritis 1 1 (100)
Pamidronate skin 1 1 (100)
Chlorambucil arthritis 1 1 (100)
Chlorambucil skin 1 1 (100)
Sodium aurothiomalate 1 1 (100)
Naproxen 1 1 (100)
Prednisone alone for arthritis 2 2 (100)
Prednisone alone for skin 2 1 (50) 1 (50)
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Authorship country affiliation The majority of the case 
reports came from the United States (18/35  %). The 
other cases originated from Japan (9/17  %), the United 
Kingdom (4/7.7  %), Spain (3/5.7  %), China (2/3.8  %), 
France (2/3.8 %), Ireland (2/3.8 %), India (1/1.9 %), Aus-
tralia (1/1.9  %), New Zealand (1/1.9  %), Italy (1/1.9  %), 
Turkey (1/1.9 %), the Netherlands (1/1.9 %), and Taiwan 
(1/1.9 %). In 5 cases it was unclear as to which country 
the authors were affiliated (Table 2).
Gender Female cases predominated (37/71  %) above 
male cases (13/25 %), with a ratio of approximately 3:1 of 
women to men. In 4  % of cases the patient gender was 
not clearly noted (Fig. 10).
Age The mean age of reported disease onset was 46 years, 
while the mean age at diagnosis was 47.5  years. The 
youngest recorded case of disease onset was 8 years old 
from the Netherlands (Havill et  al. 1999). The oldest 
recorded case of disease onset was 74 years old from the 
UK (Lonsdale-Eccles et al. 2009).
Clinical features
Associated clinical features included cutaneous involve-
ment in 50 cases (96 %), arthritis in 43 (82 %), weight loss 
in 10 (19 %), weakness in 8 (15 %), dysphagia in 5 (9.6 %), 
fatigue in 5 (9.6 %), fever in 5 (9.6 %), tenosynovitis in 3 
(5.75 %), hoarseness in 3 (5.75 %), dry eye in 3 (5.75 %), 
myalgia in 2 (3.8 %), muscle atrophy in 2 (3.8 %), mucosal 
lesions in 2 (3.8  %), and pleural effusion in 2 (3.8  %) 
(Table  3). Additionally, nodules were noted in epiglottis 
in 3 cases and in the larynx in 2 cases (3.8 %). Other fea-
tures noted (1 occurrence each) were pseudoptosis, mac-
roglossia, upper respiratory infection symptoms, parotid 
enlargement, positive PPD, lymphadenopathy, Raynaud’s 























Fig. 10 Gender distribution of the cases. Majority of the reported 
cases were female (71 %) while the rest were male. In few of the cases 
gender was not clearly reported















Nodules on epiglottis 3
Hoarseness 3
Sicca 3
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phenomenon, and splenomegaly. Concomitant medical 
conditions included Sjogren’s syndrome (3 cases), thyroid 
disease (2), hepatitis B (1), systemic lupus erythematosus 
(1), hypercholerstrolemia (1), cardiac failure (1), ulcera-
tive colitis (1), primary biliary cirrhosis (1), and multiple 
sclerosis (1).
Eleven cases (21  %) were associated with malignancy, 
but temporality with the diagnosis of MRH was not 
clearly stated. These malignancies included breast cancer 
(3), ovarian adenocarcinoma (2), ovarian neuroectoder-
mal tumor (1), cutaneous squamous cell carcinoma (1), 
melanoma (1), papillary serous endometrial cancer (1), 
nasopharyngeal cancer (1), and hepatocellular carcinoma 
(1). Additionally, 2 patients had reported prior history of 
cancer, including cervical and colon origin.
Cutaneous involvement
Of the 50 cases with cutaneous involvement, the skin 
lesions were described as “papulonodular” 28 (56  %), 
“reddish brown” nodules 16 (32  %), “papular” 7 (14  %), 
“plaque-like” 4 (8  %), “macular” 2 (4  %), “erythematous 
rash” not otherwise specified 7 (14  %), “red confluent 
non-pruritic papules” 4 (8 %), and verrucoid 1 (2 %). Three 
(6 %) cases also had papules on the eyelids, described as 
firm, nontender, and mobile (Eagle et al. 1995) (Fig. 11).
Five cases documented a skin eruption with features 
similar to those seen in dermatomyositis. For exam-
ple, one case reported pruritic and photodistributed 
erythema with telangiectasias on the trunk and neck 
(simulating the poikiloderma associated with dermato-
myositis), in addition to erythematous-to-violaceous 
papules over the extensor surfaces of the fingers (simu-
lating Gottron’s papules). This patient also had Raynaud’s 
phenomenon. However, only histopathology allowed the 
diagnosis of MRH (Muñoz-Santos et al. 2007).
Additional cutaneous findings included periungual 
papules with a coral bead appearance in 14 (28 %) cases, 
periungual telangiectasias in 2 (4  %), pruritus in 11 
(22 %), oral mucosal nodules in 7 (14 %), xanthelasma in 
5 (10 %), photodistributed erythema in 4 (8 %), bleeding 
tendency within the rash in 1 (2 %), tenderness in 1 (2 %) 
and neurofibroma-like nodules 1 (2 %) case.
Musculoskeletal involvement
Findings of inflammatory arthritis from 43 cases showed 
finger involvement in 42 (97 %). DIPs were involved in 22 
(51 %) cases, PIPs in 22 (51 %), MCPs in 12 (25 %), and 
carpometacarpal (CMC) in 4 (9 %) of cases (Fig. 12).
Other articular sited involved included the knees in 33 
(77 %), wrists in 21 (49 %), shoulders in 19 (44 %), elbows 
in 16 (37 %), ankles in 10 (23 %), hips in 6 (14 %), joints of 
foot in 5 (11.6 %), and acromioclavicular joints in 2 (4.6 %).
Erosions were seen within the radiographs in 23 (55 %) 
cases and arthritis mutilans was reported in 4 (9.3  %) 
cases. Arthralgia alone was reported in 5 (11.6 %) cases 
while tenosynovitis was seen in 3 (7 %) cases. Periarticu-
lar osteopenia was seen in 3 (7 %), while flexion deformi-
ties from long standing disease were seen in 6 (14 %) of 
cases of arthritis.
Laboratory findings
Laboratory values were reported in 38 of the 52 cases. 
Mean values included hemoglobin = 10.16 mg/dl, white 
blood cell count  =  4581.66/mm3, ESR  =  40.64  mm/h, 
C-reactive protein  =  2.46  mg/dl, and creatinine 
kinase = 318 IU/ml. Rheumatoid factor was positive in 3 
cases, anti-cyclic citrullinated peptide (CCP) was positive 
in 1 case, ANA was positive in 7 cases(the titer and dilu-
tion not recorded), anti-Ro was positive in 4, anti-La was 

























Cutaneous Manifestaons of MRH  
Fig. 11 The most common skin manifestation of MRH was papulonodular rash followed by periungual telengiectasis. Classic coral bead appear‑
ance was seen in 28 % cases
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positive in 1, and perinuclear anti-neutrophil cytoplas-
mic antibodies (P-ANCA) were positive in 1 case. Low 
C-3 and CH50 were noted in 1 case each. A positive PPD 
was seen in only 1 case.
One case recorded the urine excretion of deoxypyridi-
noline in nM/mM as 19.3(normal range being 3.20 ± 0.75 
(mean ± SD) nmol/mmol creatinine and 4.55 ± 1.22 nmol/
mmol creatinine), N-telopeptide of type I collagen (NTX) 
in nM, bone collagen equivalents (BCE)/mM creatinine 
as 102.1 (normal range for men over 18 is 21–66 and for 
women is 19–63), bone alkaline phosphatase as 19.1 units/l, 
and osteocalcin as 6.6 ng/ml (Goto et al. 2003).
Bennassar et al., recorded elevated cytokine serum lev-
els; tumor necrosis factor (TNF)-alpha level as 60 pg/ml 
(normal range 0–15 pg/ml), IL-6 as 525 pg/ml (0–5 pg/
ml); IL-8 as 23 pg/ml (0–15 pg/ml); and IL-1β as 69 pg/
ml (0–15 pg/ml) (Bennàssar et al. 2011).
Iwata et  al., recorded the serum TNF-alpha level as 
16.3  pg/ml and monocyte chemoattractant protein 
(MCP-1) level as 2790  pg/ml (normal 200–722  pg/ml) 
before treatment with infliximab 3 mg/kg. After the sec-
ond infusion of infliximab the MCP-1 level decreased to 
1350  pg/ml but the TNF-alpha level had increased (no 
values given) (Iwata et al. 2012).
Histologic analysis
Synovial biopsy was done in 6 cases. Consistent find-
ings included nodular infiltrate of plump histiocytes with 
abundant finely granular eosinophilic cytoplasm and 
multinucleated giant cells, and usually PAS positivity, 
diastase-resistant. Other finding noted cells with CD68 
immunoreactivity, which failed to stain with S100 or 
CD1a (Hiramanek et al. 2002). One case mentioned that 
there was villous hypertrophic synovitis. Some degree of 
fibrosis was also noted in one case (Sakamoto et al. 2002).
Skin biopsy findings were recorded in 49 cases. The skin 
biopsy was done in vast majority of cases because of ease 
of access. The skin biopsies had similar histology to the 
synovial biopsies, in addition to absence of Birbeck gran-
ules on electron microscopy, positive staining for vimen-
tin and lysozyme, prominent elastophagocytosis, and 
negative staining for Factor XIII-a, CD68 (KP-1), CD34, 
procollagen I, pan-actin, P75, CD45-RO, CD45-RA (Cox 
et al. 2001). Alcian blue stain failed to reveal interstitial 
mucin deposition in one case. Rare cases also noted posi-
tivity to alpha 1 anti-trypsin, and macrophage antigen 
compound (MAC)-387 stains (Cox et al. 2001). Addition-
ally, CD1a and S100 stains were negative, indicating that 
the histiocytes are not Langerhans cells.
Muscle biopsy was done in 2 cases, one of which was 
normal and the other showed lipid laden uniform histio-
cytes with foamy cytoplasm in nodular aggregates (Flam-
ing and Weigand 1993). Biopsy of epiglottis nodules in 1 
case showed lipid laden uniform histiocytes (Flaming and 
Weigand 1993). Hypopharyngeal nodules were biopsied 
in 1 case showing findings consistent with MRH.
Treatment comparison
The following medications were used with the number of 
instances in parentheses: prednisone (32), methotrexate 
(29), cyclophosphamide (12), nonsteroidal anti inflamma-
tory drugs (NSAIDS) (11), bisphosphonates (9), hydroxy-
chloroquine (8), etanercept (6), methylprednisolone (4), 
leflunomide (3), cyclosporine A (3), carboplatin (3), inf-
liximab (3), azathioprine (2), adalimumab (2), intra-artic-
ular steroid injection (1), sulfasalazine (1), mycophenolate 
mofetil (1), chlorambucil (1), thiotepa (1), thalidomide 
(1), cisplatin (1), paclitaxel (1), sodium aurothiomalate 
(1), and minocycline (1). References (Islam et  al. 2013; 
Zelger et  al. 1996; Weber and Freudenthal 1937; Goltz 
and Laymon 1954; Barrow and Holubar 1969; Lesher and 
Allen 1984; Tajirian et  al. 2006; Luz et  al. 2001; Trotta 
et al. 2004; Havill et al. 1999; Lonsdale-Eccles et al. 2009; 
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Arcular Involvement Reported in MRH  
Fig. 12 Hand involvement was the most common region with almost equal involvement of distal and proximal interphalangeal joints. Knee was 
the second most commonly involved joint with MRH
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et al. 2011; Iwata et al. 2012; Hiramanek et al. 2002; Saka-
moto et al. 2002; Cox et al. 2001; Flaming and Weigand 
1993; Olson et  al. 2015; Aouba et  al. 2015; Eagle et  al. 
1995; Han et al. 2012; Teo and Goh 2009; Kishikawa et al. 
2007; Valencia et al. 1998; Shiokawa et al. 1991; Moreau 
et al. 1992; Lambert and Nuki 1992; Qureshi et al. 1993; 
Gibson et  al. 1995; Franck et  al. 1995; Liang and Gran-
ston 1996; Kocanaogullari et al. 1996; Gorman et al. 2000; 
Morris-Jones et al. 2000; Hsu et al. 2001; Saito et al. 2001; 
Santilli et al. 2002; Blanco et al. 2002; Outland et al. 2002; 
Hsiung et  al. 2003; Matejicka et  al. 2003; Liu and Fang 
2004; Kovach et  al. 2004; Shannon et  al. 2005; Mavra-
gani et al. 2005; Malik et al. 2005; Gajic-Veljic et al. 2006; 
Adamopoulos et  al. 2006; Chen et  al. 2006; Chauhan 
et al. 2007; de Zwart-Storm et al. 2007; Codriansky et al. 
2008; Satoh et al. 2008; Kalajian and Callen 2008; Broad-
well et al. 2010; Kaul et al. 2010; Fett and Liu 2011; Mun 
et  al. 2012; Yeter and Arkfeld 2013) and summarized in 
Table 1.
In cases using methotrexate for arthritis (25 cases), 
treatment resulted in a score of 3 (complete resolution of 
symptoms) in 28 % cases, a score of 2 (partial response) in 
44 % of cases, a score of 1 (no benefit) in 12 % cases, and 
worsening of symptoms (score = 0) in 16 %. When treat-
ing for skin involvement (26 cases), treatment resulted in 
a score of 3 in 38 %, a score 2 in 28 %, a score of 1 in 11 %, 
and a score of 0 in 11 % of cases.
In case of cyclophosphamide use for the arthritis (10 
cases), a treatment score of 3 was seen in 20 % cases, a 
score of 2 in 40 % of cases, and a score of 1 in 40 % cases. 
Use for skin lesions (11 cases), demonstrated treatment 
scores of 3 in 27 % cases, a score of 2 in 45 % cases, and a 
score of 1 in 27 % cases.
Hydroxychloroquine was used in 7 cases for both 
arthritis and skin lesions. No patients reached a treat-
ment score of 3. A score of 2 was seen in 14 % of patients, 
a score of 1 in 43 % cases, and score of 0 in 43 % cases.
Azathioprine was used in 2 cases. One case had a score 
of 3 for skin and arthritis symptoms. The other case had 
a score of 2 for the skin symptoms and a score of 1 for 
the arthritis. Leflunomide was used in 2 cases and yielded 
score of 3 for skin and arthritis in both cases. Sulfasala-
zine use in 1 case resulted in a worse outcome (score 0) 
for skin and arthritis. Thalidomide use in 1 case resulted 
in partial response (score 2). Gold salts (sodium aurothi-
omalate) were used in 1 case with no benefit (score 1). 
Similarly chlorambucil use was found to be ineffective, 
in fact worsening the disease in 1 case (score 0). Nap-
roxen use in 1 case of pediatric disease onset resulted 
in complete resolution of symptoms. Although steroids 
were widely used, in 2 cases prednisone was used with-
out any disease modifying anti-rheumatic drugs DMARD 
resulting in complete skin resolution in 1 case and partial 
response in the other. In both of these cases, the treat-
ment for arthritis symptoms were partially beneficial 
without complete resolution (score 2).
Biological agents used included etanercept, adali-
mumab and infliximab. Etanercept was used in 6 cases 
giving complete response in 3, partial response in 2 and 
no benefit in 1 case. Adalimumab was used in 2 cases, 
resulting in complete response in both cases (score 3). 
Infliximab was used in 3 cases with complete response in 
1 and partial response in 2 cases.
A recent case report mentions using Anakinra (IL-1 
inhibition), which allowed control of the disease (score 3) 
(Aouba et al. 2015).
Bisphosphonates used included alendronate, zolen-
dronic acid and pamidronate. Alendronate was used in 4 
cases with scores for arthritis as follows: a score of 3 in 
1 case, a score of 2 in 2 cases, and a score of 3 in 1 case. 
For skin lesions, treatment resulted in a score of 3 in 2 
cases and a score 2 and 1 in 1 case each. Zolendronic acid 
use for arthritis resulted in treatment scores of 3 in 1 case 
and 2 in 2 cases. The use for skin symptoms resulted in a 
score of 3 in 1 case and a score of 2 in 1 case. Pamidronate 
use in 1 case resulted in score of 2 for arthritis, but only a 
score of 1 for skin symptoms.
Combination drug use and second line therapies In 18 
cases methotrexate was initiated either after or concomi-
tant with prednisone. This combination alone seemed to 
be successful in 10 cases (score of 3). Other medications 
were also combined with methotrexate, including 1 case 
with cyclophosphamide which controlled disease (score 
3), 3 cases with hydroxychloroquine which did not pro-
vide sufficient disease control (score 2). The addition of 
cyclophosphamide or chlorambucil was also sub opti-
mally effective and finally combination of methotrexate 
and etanercept controlled the disease. In two cases after 
using methotrexate alone, etanercept was added and was 
suboptimal (score 2), subsequent switching to inflixi-
mab was found effective in one case (score 3) and in the 
other leflunomide was combined with etanercept with an 
improved response (score 3). In 1 case each, using clo-
dronate and zoledronic acid plus methotrexate was effec-
tive (score 3) after methotrexate alone was suboptimal 
(score 2). In 1 case of MRH associated with ovarian can-
cer, a combination of surgical excision of the cancer and 
chemotherapy lead to resolution of the MRH.
Prednisone alone was started in 6 patients with control 
of symptoms in 2 cases (3 score). In the rest, concomi-
tant use of cyclophosphamide was successful (1 case with 
score of 3), methotrexate was effective in 3 cases (score 
3), and cyclophosphamide plus methotrexate was use-
ful in 1 case (score 3). In 1 case, use of prednisone with 
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cyclosporine was of benefit (score 3) after suboptimal 
response with cyclophosphamide (score 2).
In one case with suboptimal benefit on the combina-
tion of etanercept and methotrexate (score of 2), use of 
adalimumab yielded better disease control (score 3).
In 4 cases with concomitant malignancy using chemo-
therapy and surgery for the primary cancer resulted in 
MRH remission as well (Han et  al. 2012; Teo and Goh 
2009; Kishikawa et al. 2007; Valencia et al. 1998).
Discussion
Our results indicate that MRH is a worldwide disease 
with cases from around the globe and from various eth-
nic/racial backgrounds. More reports in White patients 
from Western countries may be attributed to higher 
awareness of the disease in these populations. MRH is 
easy to mistake for other inflammatory joint conditions 
such as rheumatoid arthritis or psoriatic arthritis, but the 
distinctive clinical, radiographic, and histologic features 
can aid in differentiating these diseases. Early disease 
may be difficult to diagnose prior to development of bone 
erosions. As the disease progresses, joint space narrow-
ing of the distal interphalangeal DIPs, marginal erosions, 
and absence of new bone formation is a unique feature 
of MRH. Joint space narrowing and periarticular osteo-
penia may be present. Arthritis mutilans may be seen in 
untreated advanced disease (Islam et al. 2013). Although 
hands are affected most commonly, we found almost all 
the appendicular joints can be affected including wrists, 
elbows, shoulders, hips, knees, ankle, and the feet con-
sistent with earlier reports (Barrow and Holubar 1969).
Our review found a significant female predominance 
with a ratio of 2.84:1 female to males, consistent with 
prior reports. The mean age of disease onset as 46 years, 
consistent with prior estimates, with the youngest case 
being an 8-year-old girl and the oldest age was 74 years. 
Since the conclusion of our review, a recent case report 
mentioned the occurrence of MRH in a 2-year-old girl 
(Olson et al. 2015).
Almost all the cases had either preceding or simultane-
ous cutaneous lesions which were variably described as 
“reddish brown nodules” or “papulo-nodular” in most 
cases. Other patterns described included “macular,” “pap-
ular,” and rarely “verrucoid.” A nonspecific “erythematous 
rash” was seen in few cases. In our case, and prior reports 
in the literature, the cutaneous eruption can mimic the 
findings seen in dermatomyositis such as findings that 
can be mistaken for poikiloderma, Gottron’s papules, and 
a heliotrope rash. Appropriate clinical, radiographic, and 
histologic correlation is necessary for accurate diagnosis 
of MRH.
At this time, if skin lesions are present, skin biopsy is 
the best test to diagnose MRH due to an absence of any 
unique biomarker for this disease. Generally there is 
negativity for rheumatoid factor, anti-CCP, ANA, and 
ANCA. ESR is typically elevated (mean of 40 mm/h), as is 
CRP (mean of 2.46 mg/dl.
Previously proposed treatment regimens have sug-
gested use of NSAIDS in early and mild disease, or when 
treating the pediatric populations. However, given the 
general aggressive nature of this disease, early use of 
DMARD should be initiated once the diagnosis is made. 
Early use of steroids should be strongly considered, as 
there is evidence of benefit in this review with prednisone 
alone or in combination with other agents. Prednisone 
may be used initially in a moderate dose (7.5–≤30  mg/
day) and then tapered to a lower dose (≤7.5  mg/day) 
based on clinical activity. Chronic low doses of pred-
nisone may be required to control disease.
Our review shows that the most effective initial 
DMARD to use is methotrexate, which controlled arthri-
tis symptoms (score 3) in 28  % cases and skin lesions 
in 38  %. Additionally, it showed partial disease control 
(score 2) in joints in 44 % and skin lesions in 28 % cases 
respectively. Other DMARDs such as leflunomide or 
azathioprine may be considered in cases with a contrain-
dication to methotrexate. Other agents like hydroxychlo-
roquine and sulfasalazine were not of significant benefit. 
Hydroxychloroquine may be considered as a combined 
agent.
Cyclophosphamide was found to be of significant ben-
efit with 20  % of cases with complete (score 3) arthritis 
resolution and 27  % cases of skin lesions. Additionally 
partial arthritis and skin disease control (score 2) was 
seen in 40 and 45 % cases respectively. Today given the 
era of biologics, with relatively less systemic side effects 
and hassle of monitoring side effects, this powerful agent 
may be kept in reserve for refractory diseases or in cases 
of major extra-articular manifestations.
As new biologics are becoming available in rapid suc-
cession, it is prudent to incorporate these agents into our 
armamentarium to treat MRH. However, given the low 
number of case reports it is difficult to assess superiority 
of one biologic over another. Etanercept use was reported 
most often (6 cases) with clear disease control achieved 
in 3 cases and partial control in 2 cases. Adalimumab 
(2 cases) and infliximab (3 cases) were also shown to be 
effective. MRH is associated with elevations in TNF lev-
els and therefore it seems logical to use anti-TNF agents 
to antagonize the disease pathway. It seems reasonable 
to combine these agents to help treat early aggressive 
disease with polyarticular or erosive disease with ele-
vated inflammatory markers. Consideration should also 
be given to adding these agents when first line agents 
are unable to achieve any significant disease control in 
4–6  weeks of follow up after initial visit. A recent case 
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report mentions using anakinra (IL-1 inhibition), which 
allowed control of the disease (Aouba et al. 2015).
Bisphosphonates should be considered as “add-on” 
agent in cases of poor disease control or in cases of con-
comitant osteopenia (or osteoporosis) and/or steroid 
use. Our review suggests clear benefit from use of these 
agents. While it would be helpful to add these agents in 
the background of other DMARDs/biologics, their use 
alone would be hard to justify. Using zoledronate may 
be considered in a patient with continued disease activ-
ity while on DMARDs, biologics, and alendronate. Bone 
turnover markers, like urine NTX, may be checked 
before starting any bisphosphonate and then monitored 
to assure adequate efficacy. These markers may cor-
relate with disease activity and may guide the choice of 
anti-resorptive agent. Elevated levels of bone turn over 
markers were shown at baseline in one case report, with 
a subsequent decrease after successful use of a bisphos-
phonate. The authors propose a treatment algorithm for 
MRH on the basis of literature review (Fig. 13).
Ultrasound can also be used to help guide treatment 
in MRH. In the current case being reported, using ultra-
sound we were able to see development of synovial pro-
liferation and increased Doppler flow, both suggestive of 
Papulo-nodular erupon and joint 
pain +/-other constuonal 
symptoms , rasied ESR/ CRP , 
negave RF, CCP or ANA  
Skin / Synovial biopsy showing non -
langerhans hisocytes, 
mulnucleated giant cells with 
ground glass cytoplasm , PAS + , 
diastase resistant , CD 68 + , an S-
100 and an CD1a negave 
Definite Diagnosis of MRH  
 #1 Mild Disease  :Prednisone (low - 
medium dose ) +/- Methotrexate (or 
other DMARD)   +/- 
NSAIDS   
Subopmal control  --> go to box #2 
#2 Moderate disease  DISEASE : 
Prednisone +Methotrexate  (or other 
DMARD)+/- Biologic  (an - TNF 
alpha)  
Subopmal response  go to #3 
#3  Severe   Disease : Prednisone 
+Methotrexate + Biologic   
Disease sll acve consider adding 
bisphosphonate  
Sll acve , consider chainging to 
other DMARDS/ Biologic  (other than 
an-TNF agents may consider 
abatacept , Rituximab, or IL-6 
inhibitor or possibly IL-1 inhibitor 
(based on clinican preference)  
Fig. 13 The algorithm summarizes the proposed treatment algorithm. For mild cases NSAIDs can be started but the disease is aggressive in most 
cases requiring steroids in varying doses and DMARDs. The Methotrexate can be used once the diagnosis is secured with biopsy. Given the erosive 
nature of the disease with possibility of joint mutilation and good response to biologic agents seen in multiple case reports especially the anti TNF 
agents, step up therapy should be considered in patients with suboptimal response to DMARDs
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continued disease activity. Additionally, ultrasound can 
help to objectively give information on erosions and soft 
tissue details of synovial and periarticular tissues.
The workup for a patient with MRH should always 
include age/gender appropriate cancer screening given 
the high association with malignancy. If concomitant 
malignancy is found, then treatment of the cancer may 
lead to resolution of the MRH (4 cases) (Eagle et al. 1995; 
Han et al. 2012; Teo and Goh 2009; Kishikawa et al. 2007). 
Additionally, the chemotherapy regimen in many cases, 
included cyclophosphamide, can also effective in treating 
MRH. Tuberculosis (TB) has an ill-defined association 
with MRH. Since we encountered only 1 case of latent 
TB, we cannot recommend routine screening. However, 
this may remain a wise exam to perform especially when 
using immunosuppressive agents to treat the disease. In 
our case, testing for TB was negative.
Given the association of MRH with osteopenia it is 
reasonable to consider a dual energy X-ray absorptiom-
etry (DEXA) scan to establish a baseline level and to treat 
appropriately with the first sign of disease. Consideration 
for bisphosphonates should be given with high Fracture 
Risk Algorithm (FRAX) scores, osteopenia, or osteopo-
rosis. Also, patients on chronic corticosteroids, even low 
dose, may receive benefit from this intervention added to 
calcium and vitamin D supplementation.
Conclusion
MRH is a rare disease but with work wide prevalence. It 
is easily possible to confuse this with other more com-
mon autoimmune inflammatory conditions like rheuma-
toid arthritis or psoriatic arthritis. This disease has some 
unique clinical and radiographic features that set it apart 
from other inflammatory arthropathies. Prompt recogni-
tion and treatment of this disease is essential because if 
left untreated this can lead to progressive joint destruc-
tion and disability. In the absence of epidemiological 
studies or randomized control data, the authors hope 
that this systemic review of literature and the treatment 
algorithm will help the clinicians better identify and treat 
this condition (Fig. 13).
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